Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Core Insights - Clearmind Medicine Inc. has announced an international patent application for a novel combination therapy using MEAI and PEA to treat obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2] - The global market for weight loss drugs is projected to grow from approximately $37 billion in 2025 to $226 billion by 2035, driven by increasing awareness of obesity as a chronic disease [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing non-hallucinogenic neuroplastogen-derived therapeutics for under-treated health issues, including obesity and liver health [4] - The company currently holds nineteen patent families, including 31 granted patents, and aims to expand its intellectual property portfolio [5] Market Potential - The MEAI-PEA combination therapy targets two significant health challenges: obesity, which affects over 890 million adults globally, and MASLD, impacting about 30% of the adult population [2][7] - This therapeutic option may provide a safer and more cost-effective alternative to GLP-1 agonists for treating obesity and MASLD [2][7]